Orchestra BioMed Holdings Inc (NASDAQ: OBIO)’s stock price has plunge by 0.35%relation to previous closing price of $2.88. Nevertheless, the company has seen a -3.02% plunge in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-18 that NEW HOPE, Pa., June 18, 2025 (GLOBE NEWSWIRE) — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced the presentation of key clinical insights into the role of AVIM therapy for the treatment of high-risk hypertension at the Congenital, Structural, and Valvular Heart Disease Interventions (“CSI”) 2025 Meeting. The data highlight AVIM therapy’s unique potential to address hypertensive heart disease, a significant and under-recognized cardiovascular syndrome that affects a growing segment of the aging hypertension population.
Is It Worth Investing in Orchestra BioMed Holdings Inc (NASDAQ: OBIO) Right Now?
Company’s 36-month beta value is 0.60.Analysts have differing opinions on the stock, with 4 analysts rating it as a “buy”, 3 as “overweight”, 0 as “hold”, and 0 as “sell”.
The public float for OBIO is 26.68M, and currently, short sellers hold a 3.98% ratio of that floaft. The average trading volume of OBIO on July 04, 2025 was 495.02K shares.
OBIO’s Market Performance
OBIO stock saw a decrease of -3.02% in the past week, with a monthly decline of -10.80% and a quarterly a decrease of -17.90%. The volatility ratio for the week is 9.11%, and the volatility levels for the last 30 days are 8.26% for Orchestra BioMed Holdings Inc (OBIO). The simple moving average for the past 20 days is -6.15% for OBIO’s stock, with a -34.72% simple moving average for the past 200 days.
Analysts’ Opinion of OBIO
Many brokerage firms have already submitted their reports for OBIO stocks, with BTIG Research repeating the rating for OBIO by listing it as a “Buy”. The predicted price for OBIO in the upcoming period, according to BTIG Research is $12 based on the research report published on March 20, 2025 of the current year 2025.
Barclays, on the other hand, stated in their research note that they expect to see OBIO reach a price target of $16. The rating they have provided for OBIO stocks is “Overweight” according to the report published on January 02nd, 2025.
B. Riley Securities gave a rating of “Buy” to OBIO, setting the target price at $15 in the report published on July 25th of the previous year.
OBIO Trading at -0.84% from the 50-Day Moving Average
After a stumble in the market that brought OBIO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -67.42% of loss for the given period.
Volatility was left at 8.26%, however, over the last 30 days, the volatility rate increased by 9.11%, as shares sank -11.35% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +1.05% upper at present.
During the last 5 trading sessions, OBIO fell by -3.02%, which changed the moving average for the period of 200-days by -50.34% in comparison to the 20-day moving average, which settled at $3.08. In addition, Orchestra BioMed Holdings Inc saw -59.41% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at OBIO starting from Fain Eric S, who sold 2,683 shares at the price of $3.05 back on Jun 26 ’25. After this action, Fain Eric S now owns 50,949 shares of Orchestra BioMed Holdings Inc, valued at $8,183 using the latest closing price.
Fain Eric S, the Director of Orchestra BioMed Holdings Inc, proposed sale 2,683 shares at $3.05 during a trade that took place back on Jun 26 ’25, which means that Fain Eric S is holding N/A shares at $8,194 based on the most recent closing price.
Stock Fundamentals for OBIO
Current profitability levels for the company are sitting at:
- -23.84% for the present operating margin
- 0.93% for the gross margin
The net margin for Orchestra BioMed Holdings Inc stands at -22.98%. The total capital return value is set at -1.58%. Equity return is now at value -179.12%, with -93.61% for asset returns.
Based on Orchestra BioMed Holdings Inc (OBIO), the company’s capital structure generated 0.11 points at debt to capital in total, while cash flow to debt ratio is standing at -25.67.
Currently, EBITDA for the company is -64.3 million with net debt to EBITDA at 0.24. When we switch over and look at the enterprise to sales, we see a ratio of 32.74. The receivables turnover for the company is 32.43for trailing twelve months and the total asset turnover is 0.05. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.35.
Conclusion
In a nutshell, Orchestra BioMed Holdings Inc (OBIO) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
